A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
about
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignanciesA phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignanciesPegylated liposomal doxorubicin in the management of ovarian cancerA phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents.IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.Characterization of the protein ubiquitination response induced by Doxorubicin.Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
P2860
Q33396761-6524C10E-AB69-41D6-B57E-6D8CCA050EFBQ33398947-AC22CB2E-5886-4D9C-AC0A-2FB6D60677C9Q33405318-DD23CFB7-6082-4DD6-8899-079F7C635C29Q34187661-6E119B2E-D370-4407-881A-AE8651815EA1Q34615116-ED08AB71-6D52-4587-8CF0-7A1CAF8D4B0AQ35218744-9364E6C4-AE40-4DB1-8704-D6DDD47DA090Q35222202-E424F001-D172-427F-90C9-5117E2817B4DQ37308719-5A3D4333-18FC-45EE-B36E-4F648E32BBF3Q37688677-75EA929C-C7E0-48E1-9845-23AAE387948DQ39358271-3A00695F-254B-4FDD-8E62-626FE2C65C3DQ39397750-4EEAFCDA-C56C-4E65-B2BB-987845921CA8Q42781343-5D9090AB-6E8E-4A51-8877-DFD8CB00C986
P2860
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
A phase I and pharmacologic st ...... s with refractory solid tumors
@ast
A phase I and pharmacologic st ...... s with refractory solid tumors
@en
type
label
A phase I and pharmacologic st ...... s with refractory solid tumors
@ast
A phase I and pharmacologic st ...... s with refractory solid tumors
@en
prefLabel
A phase I and pharmacologic st ...... s with refractory solid tumors
@ast
A phase I and pharmacologic st ...... s with refractory solid tumors
@en
P2093
P2860
P1476
A phase I and pharmacologic st ...... s with refractory solid tumors
@en
P2093
Anastasia Ivanova
Bert H O'Neil
Celeste M Lindley
Dixie Esseltine
E Claire Dees
Frances Collichio
Jason Collins
Lisa A Carey
William J Riordan
P2860
P2888
P304
P356
10.1007/S00280-008-0716-8
P577
2008-03-08T00:00:00Z
P6179
1050450303